Skip to main content


for females ages 18–99 (full criteria)
at San Francisco, California and other locations
study started
estimated completion:



The focus of this study is to evaluate the efficacy, safety, and tolerability of veliparib in women with previously untreated, Stage III or IV, high-grade serous, epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Official Title

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP Inhibitor) in Subjects With Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer


Ovarian Cancer Ovarian Neoplasm Overall Survival BRCA Veliparib Ovarian Poly Adenosine Diphosphate (ADP) - Ribose Polymerase (PARP) ABT-888 Paclitaxel Carboplatin Randomized Ovarian Neoplasms Albumin-Bound Paclitaxel


You can join if…

Open to females ages 18–99

  1. Histologic diagnosis of International Federation of Gynecology and Obstetrics (FIGO)Stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal carcinoma,with the appropriate tissue available for histologic evaluation.
  2. High-grade serous adenocarcinoma
  3. Willing to undergo testing for gBRCA.
  4. Adequate hematologic, renal, and hepatic function.
  5. Neuropathy (sensory and motor) less than or equal to Grade 1.
  6. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
  7. Participants who undergo primary cytoreductive surgery must be entered between 1 and 12 weeks after surgery. Participants undergoing interval surgery must have a tumor sample confirming the histological diagnosis prior to enrollment.
  8. Participants with measurable disease or non-measurable disease are eligible.Participants may or may not have cancer-related symptoms.
  9. Participant has one of the following available for PD analyses including somatic BRCA testing: Archived diagnostic formalin-fixed paraffin embedded (FFPE) tumor tissue; or tumor tissue biopsy collected prior to Cycle 1 Day 1.

You CAN'T join if...

  1. Endometrioid adenocarcinoma, carcinosarcoma, undifferentiated carcinoma, mixed epithelial adenocarcinoma, adenocarcinoma not otherwise specified, mucinous adenocarcinoma, clear cell adenocarcinoma, low-grade serous adenocarcinoma, or malignant Brenner's tumor.
  2. Participants with synchronous primary endometrial cancer, or a past history of endometrial cancer unless all of the following conditions are met: endometrial cancer stage not greater than IA, no vascular or lymphatic invasion, no poorly differentiated subtypes including serous, clear cell, or other FIGO grade 3 lesions.
  3. Participants with any evidence of other invasive malignancy being present within the last 3 years (with the exception of non-melanoma skin cancer). Participants are also excluded if their previous cancer treatment contraindicates this protocol's therapy.
  4. Received prior radiotherapy to any portion of the abdominal cavity or pelvis.
  5. Received prior chemotherapy for any abdominal or pelvic tumor.
  6. Clinically significant uncontrolled condition(s).
  7. Known history of allergic reaction to Cremophor-paclitaxel, carboplatin, Azo-Colourant Tartrazine (also known as FD&C Yellow 5 or E102), Azo-Colourant Orange Yellow-S (also known as FD&C Yellow 6 or E110) or known contraindications to any study supplied drug.
  8. History or evidence upon physical examination of central nervous system (CNS) disease,including primary brain tumor, any brain metastases, or history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) within 6 months of Cycle 1 Day


  • UCSF Helen Diller Family Comprehensive Cancer Center /ID# 138178
    San Francisco, California, 94158, United States
  • California Pacific Medical Center (CPMC) /ID# 138177
    San Francisco, California, 94118, United States
  • Contra Costa Oncology /ID# 143609
    Concord, California, 94520, United States
  • Cypress Womens Cancer Treatment Center /ID# 143617
    Concord, California, 94520, United States
  • Diablo Valley Oncology Hematology Medical Group /ID# 143616
    Concord, California, 94520, United States
  • John Muir Medical Center /ID# 139618
    Concord, California, 94520, United States
  • Stanford Cancer Institute /ID# 139450
    Stanford, California, 94305, United States
  • Kaiser Permanente /ID# 142051
    Vallejo, California, 94589, United States
  • Kaiser Permanente /ID# 142052
    Vallejo, California, 94589, United States
  • Kaiser Permanente /ID# 142053
    Vallejo, California, 94589, United States
  • Kaiser Permanente Medical Center /ID# 139492
    Vallejo, California, 94589, United States
  • Palo Alto Medical Foundation /ID# 139452
    Mountain View, California, 94040, United States
  • University of California, Davis Comprehensive Cancer Center /ID# 144439
    Sacramento, California, 95817, United States
  • Renown Regional Medical Center /ID# 138237
    Reno, Nevada, 89502, United States
  • Kaiser Permanente /ID# 141305
    Los Angeles, California, 90027, United States
  • UCLA /Id# 138179
    Los Angeles, California, 90095, United States
  • Long Beach Memorial Medical Center /ID# 147526
    Long Beach, California, 90806, United States
  • Medical Oncology Care Associates (MOCA) /ID# 139498
    Orange, California, 92868, United States
  • University of California, Irvine /ID# 139613
    Orange, California, 92868, United States
  • Womens Cancer Center of Nevada /ID# 138092
    Las Vegas, Nevada, 89169, United States


in progress, not accepting new patients
Start Date
Completion Date
Phase 3
Study Type
Last Updated
October 10, 2017